Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones.

[1]  M. Alam,et al.  Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. , 2011, European journal of medicinal chemistry.

[2]  M. Alam,et al.  Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Ravinesh Mishra,et al.  Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. , 2010, European journal of medicinal chemistry.

[4]  M. Alam,et al.  Synthesis and biological evaluation of some novel 6-aryl-2-(p-sulfamylphenyl)-4,5-dihydropyridazin-3(2H)-ones as anti-cancer, antimicrobial, and anti-inflammatory agents , 2010, Journal of enzyme inhibition and medicinal chemistry.

[5]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[6]  Sherif A F Rostom.  Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. , 2006, Bioorganic & medicinal chemistry.

[7]  A. Moon,et al.  Synthesis of 3-alkylthio-6-allylthiopyridazine derivatives and their antihepatocarcinoma activity , 2005 .

[8]  G. Carter,et al.  ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  A. Karaburun,et al.  Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. , 2004, European journal of medicinal chemistry.

[10]  O. Lozach,et al.  New derivatives of pyrrolo[3,4-d]pyridazinone and their anticancer effects. , 2004, Farmaco.

[11]  E. Sotelo,et al.  Pyridazine derivatives. Part 33: Sonogashira approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones☆ , 2003 .

[12]  R. Fine,et al.  A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. , 2002, Biochemical pharmacology.

[13]  A. Casini,et al.  Sulfonamides and sulfonylated derivatives as anticancer agents. , 2002, Current cancer drug targets.

[14]  G. Rastelli,et al.  Synthesis and aldose reductase inhibitory activity of a new series of benz[h]cinnolinone derivatives. , 2000, Farmaco.

[15]  T. Kinoshita,et al.  Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity. , 1999, Journal of medicinal chemistry.

[16]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[17]  M R Grever,et al.  In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.

[18]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[19]  M. Hann,et al.  Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. , 1993, Journal of medicinal chemistry.

[20]  J. Calleja,et al.  Pyridazine derivatives. XI: Antihypertensive activity of 3-hydrazinocycloheptyl[1,2-c]pyridazine and its hydrazone derivatives. , 1993, Journal of pharmaceutical sciences.

[21]  M R Grever,et al.  The National Cancer Institute: cancer drug discovery and development program. , 1992, Seminars in oncology.

[22]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[23]  B. Refouvelet,et al.  Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4H)-2-pyridazinylacetamides and 2-pyridazinylacetylhydrazides. , 1990, Chemical & pharmaceutical bulletin.

[24]  W. Moos,et al.  Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activit , 1987, Journal of medicinal chemistry.

[25]  A. Monge,et al.  Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds. , 1987, Journal of medicinal chemistry.

[26]  E. Schwenk,et al.  beta-Aroylacrylic acids. , 1948, Journal of the American Chemical Society.

[27]  H. G. Oddy.  SOME PREPARATIONS FROM MALEIC AND FUMARIC ACIDS , 1923 .